Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Open Access
- 22 March 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 12 (1), 104
- https://doi.org/10.1186/1471-2407-12-104
Abstract
RRM1 and ERCC1 overexpression has been extensively investigated as potential predictive markers of tumor sensitivity to conventional chemotherapy agents, most thoroughly in lung cancer. However, data in pancreatic cancer are scarce.Keywords
This publication has 42 references indexed in Scilit:
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ AnalysisThe American Journal of Pathology, 2011
- pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to mRNAsPLOS ONE, 2010
- Iron Deficiency and Acute Seizures: Results from Children Living in Rural Kenya and a Meta-AnalysisPLOS ONE, 2010
- Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinomaBritish Journal of Cancer, 2010
- Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine KinaseCancer Research, 2009
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer, 2008
- Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?British Journal of Cancer, 2007
- Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cellsBritish Journal of Cancer, 2007